Therapeutic Effect of Anti-GD2 Antibody IL-2 Fusion Protein on Established Experimental Metastasis of NXS2 Cells in C.B-17 SCID Mice
| Treatment* . | Metastatic Score† . | Metastatic Score‡ . | Weight (mg) . |
|---|---|---|---|
| Bone Marrow | Liver | Liver | |
| PBS | 2, 2, 2, 2, 2, 2 | 4, 4, 4, 4, 3, 2 | 4,502 ± 1,113 |
| ch14.18 + IL2 | 2, 2, 2, 2 | 4, 4, 4, 3 | 3,145 ± 780 |
| ch14.18–IL22-153 | 0, 0, 0, 0 | 0, 0, 0, 0 | 1,028 ± 37 |
| Treatment* . | Metastatic Score† . | Metastatic Score‡ . | Weight (mg) . |
|---|---|---|---|
| Bone Marrow | Liver | Liver | |
| PBS | 2, 2, 2, 2, 2, 2 | 4, 4, 4, 4, 3, 2 | 4,502 ± 1,113 |
| ch14.18 + IL2 | 2, 2, 2, 2 | 4, 4, 4, 3 | 3,145 ± 780 |
| ch14.18–IL22-153 | 0, 0, 0, 0 | 0, 0, 0, 0 | 1,028 ± 37 |
Experimental bone marrow and liver metastases were induced by intravenous injection of 5 × 104 NXS2 hybrid neuroblastoma cells.
Treatment was initiated at day 5 after tumor cell inoculation by daily intravenous injections ×6 of either PBS, 40 μg ch14.18 antibody + 120,000 IU rhIL-2, or 40 μg ch14.18–IL-2 fusion protein.
Bone marrow metastases were staged according to results obtained by high- and low-sensitivity tyrosine hydroxylase RT-PCR as described in Materials and Methods.
Liver metastases were staged according to the percentage of metastatic liver surface: 0, 0%; 1 <0% to 25%; 2, 25% to 50%; 3, 50% to 75%; 4 ≥75%.
Differences in bone marrow staging, numbers of metastatic liver foci, and liver weights between fusion protein treatment and all control groups were statistically significant (P < .001).